These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 23018838)

  • 1. EGFR through STAT3 modulates ΔN63α expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas.
    Ripamonti F; Albano L; Rossini A; Borrelli S; Fabris S; Mantovani R; Neri A; Balsari A; Magnifico A; Tagliabue E
    J Cell Physiol; 2013 Apr; 228(4):871-8. PubMed ID: 23018838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility.
    Bajetto A; Porcile C; Pattarozzi A; Scotti L; Aceto A; Daga A; Barbieri F; Florio T
    J Biol Regul Homeost Agents; 2013; 27(1):143-54. PubMed ID: 23489694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.
    Takaoka S; Iwase M; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
    Int J Oncol; 2007 Jun; 30(6):1469-76. PubMed ID: 17487368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR codon 497 polymorphism - implications for receptor sensitivity to inhibitors in HNSCC cell lines.
    Krohn V; Wiegand S; Werner JA; Mandic R
    Anticancer Res; 2011 Jan; 31(1):59-65. PubMed ID: 21273581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.
    Carrasco-García E; Saceda M; Grasso S; Rocamora-Reverte L; Conde M; Gómez-Martínez A; García-Morales P; Ferragut JA; Martínez-Lacaci I
    Exp Cell Res; 2011 Jun; 317(10):1476-89. PubMed ID: 21439954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor.
    Mandic R; Rodgarkia-Dara CJ; Zhu L; Folz BJ; Bette M; Weihe E; Neubauer A; Werner JA
    FEBS Lett; 2006 Sep; 580(20):4793-800. PubMed ID: 16904111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor.
    Shao H; Cheng HY; Cook RG; Tweardy DJ
    Cancer Res; 2003 Jul; 63(14):3923-30. PubMed ID: 12873986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
    Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of EGFR immunoexpression on STAT3 activation and association with proinflammatory/regulatory cytokine pattern in laryngeal squamous cell carcinoma.
    Starska K; Brys M; Forma E; Glowacka E; Lewy-Trenda I; Stasikowska O; Krajewska WM; Lukomski M
    Oncol Rep; 2009 Feb; 21(2):539-48. PubMed ID: 19148533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intercellular contact augments epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3)-activation which increases podoplanin-expression in order to promote squamous cell carcinoma motility.
    Fujii M; Honma M; Takahashi H; Ishida-Yamamoto A; Iizuka H
    Cell Signal; 2013 Apr; 25(4):760-5. PubMed ID: 23266472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes.
    Quadros MR; Peruzzi F; Kari C; Rodeck U
    Cancer Res; 2004 Jun; 64(11):3934-9. PubMed ID: 15173005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
    Johnson FM; Saigal B; Donato NJ
    J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
    Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway.
    Yang J; Liao D; Chen C; Liu Y; Chuang TH; Xiang R; Markowitz D; Reisfeld RA; Luo Y
    Stem Cells; 2013 Feb; 31(2):248-58. PubMed ID: 23169551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRD4 Regulates Transcription Factor ΔNp63α to Drive a Cancer Stem Cell Phenotype in Squamous Cell Carcinomas.
    Fisher ML; Balinth S; Hwangbo Y; Wu C; Ballon C; Wilkinson JE; Goldberg GL; Mills AA
    Cancer Res; 2021 Dec; 81(24):6246-6258. PubMed ID: 34697072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas.
    Nestor M; Sundström M; Anniko M; Tolmachev V
    Nucl Med Biol; 2011 Jan; 38(1):103-12. PubMed ID: 21220133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ΔNp63α Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas.
    Abraham CG; Ludwig MP; Andrysik Z; Pandey A; Joshi M; Galbraith MD; Sullivan KD; Espinosa JM
    Cell Rep; 2018 Sep; 24(12):3224-3236. PubMed ID: 30232004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100A7 acts as a dual regulator in promoting proliferation and suppressing squamous differentiation through GATA-3/caspase-14 pathway in A431 cells.
    Li T; Qi Z; Kong F; Li Y; Wang R; Zhang W; Shang Y; Huang L; He D; Xiao X
    Exp Dermatol; 2015 May; 24(5):342-8. PubMed ID: 25651379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.